The panel discussed ALL treatment, associated toxicities, and the possibility of a chemotherapy-free approach. The panel mainly discussed frontline tyrosine kinase inhibitors for the treatment of chronic phase CML. Live in Chicago, this podcast episode features a panel discussion on unanswered questions in AML.